Cyto-Facto Inc. began manufacturing gene and cell preparations to meet a worldwide need for new treatments that leverage a patient’s immune system to fight disease. CF implemented the Vaisala viewLinc continuous monitoring system to ensure compliance with strict GCTP regulations. In April 2023, Cyto-Facto Inc. (CF), a spin-off of the…